Newsletter registration

By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Dynamic Business Location.

Coronavirus: Government Commits € 23 Million to Fund Drug Research


"Conducting research in the battle against the virus is the most effective means to quickly develop a vaccine and medicines. The financial boost enables us to accelerate research, and we want to conduct clinical research on those drugs which are far advanced as quickly as possible", says Margarete Schramböck, Federal Minister for Digital and Economic Affairs. "Every day counts in the fight against the coronavirus. We have several of the world's best scientists in this sector in the country. We want to support their work", states Leonore Gewessler, Federal Minister for Climate Action, Environment, Energy, Mobility, Innovation and Technology, commenting on the initiative.

Heinz Faßmann, Federal Minister for Education, Science and Research, is also lending his support. "As an accompanying measure, we will provide an additional € 2 million to the medical universities so that they can participate in the clinical studies together with the companies. Austria is well positioned in the field of life sciences, from basic research to production and sales".

Applications can be submitted to the Austrian Research Promotion Agency (FFG) at Two deadlines have been set (8 April 2020, 11 May 2020) to provide a basis for quick decisions and thus a rapid start of the projects. The accelerated process is designed to enable research activities to be launched as fast as possible. Companies based in Austria working on active substances to combat COVID-19 or the consequences of the coronavirus (e.g. pneumonia) and who want to quickly initiate a clinical study (Phase I or II) can apply for funding. Funding will be provided to cover all costs related to the studies, for example personnel and material costs for assessment teams. No limitation exists on third-party costs.

"Austria is a strong life sciences location with the potential to quickly develop new drugs and carry out tests in clinical studies. The additional funds provide the basis for us to support researchers and companies to stand up to the coronavirus", according to Henrietta Egerth and Klaus Pseiner, Managing Directors of the Austrian Research Promotion Agency (FFG).

SERVICE: All the relevant information on funding and the possibility to submit funding applications is available at

Source: BMDW


Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin



Meet us at events, seminars and trade shows - worldwide.

  • 18° Salone d’Impresa

    29. / 30.05.2020, Online

Austria Map

Find the perfect location for your company

A country like Austria considered to be an especially good terrain for upscale industrial segments, and with a particular emphasis on research and environmental friendliness, represents a major opportunity for SIAD. Our corporate goal is namely to assist the customer and provide support in improving the productivity and the environmental compatibility of its work processes.


More testimonials

news from the business location Austria

Less gold is sometimes better

Using an ultra-thin gold layer, scientists at the Vienna University of Technology succeeded in creating an almost optimal infrared absorber.

Support measures for companies affected by COVID-19

To stimulate the economy, either new programs may be established as a result of the draft law or existing support programs (e.g. aws, ÖHT) will be expanded. All measures introduced are intended to be applicable immediately and will be in force until the end of 2020. The measures currently introduced include the following areas:

More news All blog posts